CA2213368A1 - Polyetherester copolymers as drug delivery matrices - Google Patents

Polyetherester copolymers as drug delivery matrices

Info

Publication number
CA2213368A1
CA2213368A1 CA002213368A CA2213368A CA2213368A1 CA 2213368 A1 CA2213368 A1 CA 2213368A1 CA 002213368 A CA002213368 A CA 002213368A CA 2213368 A CA2213368 A CA 2213368A CA 2213368 A1 CA2213368 A1 CA 2213368A1
Authority
CA
Canada
Prior art keywords
active agent
biologically active
drug delivery
copolymer
delivery matrices
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002213368A
Other languages
French (fr)
Other versions
CA2213368C (en
Inventor
Jacob Hillebrand Goedemoed
Wilhelmus Everhardus Hennink
Jeroen Mattijs Bezemer
Jan Feijen
Clemens Antoni Van Blitterswijk
Joost Dick De Bruijn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OCTOPLUS POLYACTIVE SCIENCES BV
Biolex Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2213368A1 publication Critical patent/CA2213368A1/en
Application granted granted Critical
Publication of CA2213368C publication Critical patent/CA2213368C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

A composition for delivering a biologically active agent to a host. The composition comprises a product including a biologically active agent encapsulated in a matrix comprising a copolymer, of a polyalkylene glycol and an aromatic polyester, such as a polyethylene glycol terephthalate/-polybutylene terephthalate copolymer. The polyether-ester copolymer protects the biologically active agent (including proteins, peptides, and small drug molecules) from degradation or denaturation and provides and essentially zero-order release.
CA002213368A 1996-08-16 1997-08-18 Polyetherester copolymers as drug delivery matrices Expired - Fee Related CA2213368C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/699,896 US5980948A (en) 1996-08-16 1996-08-16 Polyetherester copolymers as drug delivery matrices
US08/699,896 1996-08-16

Publications (2)

Publication Number Publication Date
CA2213368A1 true CA2213368A1 (en) 1998-02-16
CA2213368C CA2213368C (en) 2008-04-01

Family

ID=24811379

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002213368A Expired - Fee Related CA2213368C (en) 1996-08-16 1997-08-18 Polyetherester copolymers as drug delivery matrices

Country Status (9)

Country Link
US (1) US5980948A (en)
EP (2) EP1247522B1 (en)
AT (2) ATE267006T1 (en)
CA (1) CA2213368C (en)
DE (2) DE69726672T2 (en)
DK (2) DK1247522T3 (en)
ES (2) ES2212037T3 (en)
PT (2) PT830859E (en)
WO (1) WO1998006439A1 (en)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842657A1 (en) * 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
FR2777895A1 (en) * 1998-04-28 1999-10-29 Debio Rech Pharma Sa Non crosslinked block polymer useful as support for active agents e.g. antigens and vaccines
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
US6656489B1 (en) 1999-02-10 2003-12-02 Isotis N.V. Scaffold for tissue engineering cartilage having outer surface layers of copolymer and ceramic material
EP1038538A1 (en) * 1999-03-19 2000-09-27 IsoTis B.V. Muscle tissue engineering
WO2000062759A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Dry, mouldable drug formulation
EP1068872A1 (en) * 1999-07-12 2001-01-17 IsoTis B.V. Sutures
JP2001054563A (en) * 1999-07-12 2001-02-27 Isotis Bv Suture
AU6510400A (en) * 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
ATE453414T1 (en) * 1999-08-06 2010-01-15 Chienna Bv SHAPING A POLYMER
EP1090928B1 (en) * 1999-09-30 2004-05-26 Chienna B.V. Polymers loaded with bioactive agents
CA2321321A1 (en) * 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
ATE355813T1 (en) * 2000-07-14 2007-03-15 Novo Nordisk As METHOD FOR FORMING A PHARMACEUTICAL COMPOSITION IN A PACKAGING MATERIAL
EP1247537A1 (en) * 2001-04-04 2002-10-09 Isotis B.V. Coating for medical devices
US6565884B2 (en) 2001-09-10 2003-05-20 Interpore Cross International Bone graft material incorporating demineralized bone matrix and lipids
US7357947B2 (en) * 2001-09-10 2008-04-15 Biomet, Inc. Bone graft material incorporating demineralized bone matrix and lipids
AU2002343681B2 (en) * 2001-11-12 2006-07-06 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
AU2002353661A1 (en) * 2002-02-26 2003-09-09 Chienna B.V. Biodegradable polymeric material for biomedical applications
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
US6926919B1 (en) * 2003-02-26 2005-08-09 Advanced Cardiovascular Systems, Inc. Method for fabricating a coating for a medical device
NZ542548A (en) 2003-03-31 2009-04-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
US20040215318A1 (en) * 2003-04-24 2004-10-28 Brian Kwitkin Timed delivery of therapeutics to blood vessels
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
AU2005211362B2 (en) 2004-02-02 2008-03-13 Ambrx, Inc. Modified human interferon polypeptides and their uses
CA2575740A1 (en) * 2004-03-24 2005-10-13 Doctor's Research Group, Inc. Methods of performing medical procedures that promote bone growth, methods of making compositions that promote bone growth, and apparatus for use in such methods
EP1732619A1 (en) 2004-03-26 2006-12-20 SurModics, Inc. Composition and method for preparing biocompatible surfaces
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20060018948A1 (en) * 2004-06-24 2006-01-26 Guire Patrick E Biodegradable implantable medical devices, methods and systems
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
MX2007000728A (en) 2004-07-21 2007-03-15 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids.
US7311980B1 (en) * 2004-08-02 2007-12-25 Advanced Cardiovascular Systems, Inc. Polyactive/polylactic acid coatings for an implantable device
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
GB0426822D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
GB0426823D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
EP1836316A4 (en) 2004-12-22 2009-07-22 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
JP4990792B2 (en) * 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド Compositions of aminoacyl-tRNA synthetases and uses thereof
US20060147491A1 (en) * 2005-01-05 2006-07-06 Dewitt David M Biodegradable coating compositions including multiple layers
US20060198868A1 (en) * 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
ATE529442T1 (en) * 2005-06-03 2011-11-15 Ambrx Inc IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES
CN103103238B (en) 2005-08-18 2016-08-10 Ambrx公司 A kind of manufacture in cell has selected amino acid whose antibody or the method for antibody fragment polypeptide in specific location
AU2006311568B2 (en) * 2005-11-08 2010-11-11 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
EP1951890A4 (en) * 2005-11-16 2009-06-24 Ambrx Inc Methods and compositions comprising non-natural amino acids
EP3058972A1 (en) 2005-11-17 2016-08-24 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
DK1968635T3 (en) * 2005-12-14 2014-12-15 Ambrx Inc Compositions and Methods of, and uses of non-natural amino acids and polypeptides
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
JP2009542671A (en) * 2006-06-28 2009-12-03 サーモディクス，インコーポレイティド Active agent elution matrix containing fine particles
MX2009002526A (en) * 2006-09-08 2009-04-16 Ambrx Inc Suppressor trna transcription in vertebrate cells.
DK2061878T3 (en) * 2006-09-08 2014-04-07 Ambrx Inc HYBRID SUPPRESSOR TRNA FOR ANIMAL CELLS
EP2615108B1 (en) * 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
WO2008073295A2 (en) * 2006-12-07 2008-06-19 Surmodics, Inc. Latent stabilization of bioactive agents releasable from implantable medical articles
ATE554785T1 (en) 2007-03-30 2012-05-15 Ambrx Inc MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2152743A2 (en) 2007-05-23 2010-02-17 Allergan, Inc. Cross-linked collagen and uses thereof
US20090022805A1 (en) * 2007-06-28 2009-01-22 Joram Slager Polypeptide microparticles having sustained release characteristics, methods and uses
US8709827B2 (en) * 2007-06-28 2014-04-29 Surmodics, Inc. Polypeptide microparticles
EP2175865A4 (en) * 2007-07-25 2012-01-11 Biolex Therapeutics Inc Controlled release interferon drug products and treatment of hcv infection using same
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US9138509B2 (en) * 2007-09-14 2015-09-22 Musculoskeletal Transplant Foundation Composition for filling bone defects
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
EP2055299A1 (en) 2007-10-23 2009-05-06 Koninklijke Philips Electronics N.V. Methods for preparing polymer microparticles
SI2818184T1 (en) 2007-11-16 2019-03-29 Aclaris Therapeutics, Inc. Compositions and methods for treating Purpura
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
DE102007062113B4 (en) * 2007-12-21 2011-05-12 Bettina Lingenfelder Dermatological preparation
EP2235266A1 (en) * 2007-12-21 2010-10-06 3M Innovative Properties Company Retroreflective pavement markings
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
WO2009091812A2 (en) * 2008-01-14 2009-07-23 Surmodics, Inc. Devices and methods for elution of nucleic acid delivery complexes
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
US8951545B2 (en) 2008-03-28 2015-02-10 Surmodics, Inc. Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery
WO2009126830A2 (en) * 2008-04-09 2009-10-15 Surmodics, Inc. Delivery of nucleic acid complexes from materials including negatively charged groups
US8496954B2 (en) * 2008-04-18 2013-07-30 Surmodics, Inc. Coating systems for the controlled delivery of hydrophilic bioactive agents
EP2829265B1 (en) 2008-04-28 2016-08-24 Zogenix, Inc. Novel formulations for treatment of migraine
EP2296630A2 (en) * 2008-05-07 2011-03-23 SurModics, Inc. Delivery of nucleic acid complexes from particles
CA2730498A1 (en) * 2008-07-14 2010-01-21 Surmodics, Inc. Medical devices and methods for delivery of nucleic acids
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
AU2009288118B2 (en) 2008-09-02 2014-12-11 Allergan, Inc. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
WO2010031007A2 (en) 2008-09-12 2010-03-18 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
CN102232085A (en) 2008-09-26 2011-11-02 Ambrx公司 Modified animal erythropoietin polypeptides and their uses
MX2011003196A (en) 2008-09-26 2011-04-27 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines.
US8883208B2 (en) * 2009-04-08 2014-11-11 Surmodics, Inc. Particles for delivery of nucleic acids and related devices and methods
WO2010118238A2 (en) * 2009-04-08 2010-10-14 Surmodics, Inc. Controlled release devices and methods for delivery of nucleic acids
US8246576B2 (en) 2009-05-18 2012-08-21 Surmodics, Inc. Method and apparatus for delivery of a therapeutic agent with an expandable medical device
MX349301B (en) 2009-12-21 2017-07-21 Ambrx Inc Modified bovine somatotropin polypeptides and their uses.
BR112012015597A2 (en) 2009-12-21 2017-01-31 Ambrx Inc modified porcine somatotropin peptides and their uses
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
NZ602405A (en) 2010-03-12 2014-12-24 Allergan Ind Sas A fluid composition comprising a hyaluronan polymer and mannitol for improving skin conditions
PT2550027T (en) 2010-03-22 2016-08-12 Allergan Inc Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
US20110319473A1 (en) 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
EP2859887B1 (en) 2010-07-09 2017-03-22 InnoCore Technologies B.V. Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides
HUE045845T2 (en) 2010-08-17 2021-12-28 Ambrx Inc Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
US20120100187A1 (en) 2010-10-26 2012-04-26 Surmodics, Inc. Coatings and methods for controlled elution of hydrophilic active agents
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
US10213529B2 (en) 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
US9861727B2 (en) 2011-05-20 2018-01-09 Surmodics, Inc. Delivery of hydrophobic active agent particles
FR2975301B1 (en) 2011-05-20 2013-05-24 Flamel Tech Sa COMPOSITION COMPRISING AN ALPHA INTERFERON
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
CA2838237C (en) 2011-06-03 2020-05-26 Allergan, Inc. Dermal filler compositions including antioxidants
EP3081937B1 (en) 2011-07-18 2019-11-13 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
EP2734573B1 (en) 2011-07-22 2021-09-08 InnoCore Technologies Holding B.V. Biodegradable, semi-crystalline, phase separated, thermoplastic multi block copolymers for controlled release of biologically active compounds
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
ES2907763T3 (en) 2012-08-31 2022-04-26 Sutro Biopharma Inc Modified amino acids comprising an azido group
US11246963B2 (en) 2012-11-05 2022-02-15 Surmodics, Inc. Compositions and methods for delivery of hydrophobic active agents
JP6438406B2 (en) 2012-11-05 2018-12-12 サーモディクス，インコーポレイテッド Compositions and methods for delivering hydrophobic bioactive agents
WO2014167440A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Modified release pharmaceutical compositions of cyclobenzaprine or salts thereof
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
FR3007972B1 (en) 2013-07-04 2015-08-07 Oreal COSMETIC COMPOSITION COMPRISING LIQUID FATTY ESTERS, VOLATILE OILS AND THICKENERS, AND COSMETIC TREATMENT PROCESS
ES2658039T3 (en) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3083658B1 (en) 2013-12-18 2019-05-08 President and Fellows of Harvard College Crp capture/detection of gram positive bacteria
WO2015150948A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
WO2016040347A2 (en) 2014-09-08 2016-03-17 University Of Iowa Research Foundation Microrna inhibitor system and methods of use thereof
ES2761558T3 (en) 2014-09-30 2020-05-20 Allergan Ind Sas Stable hydrogel compositions including additives
EA036697B1 (en) 2014-10-24 2020-12-09 Бристол-Майерс Сквибб Компани Modified fgf-21 polypeptides and uses thereof
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
CA2986702C (en) 2015-05-21 2023-04-04 David Wang Modified demineralized cortical bone fibers
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
US10273476B2 (en) 2016-04-30 2019-04-30 University Of Iowa Research Foundation MicroRNA-200 based approaches for modulating bone formation inhibition and bone regeneration
RU2617049C1 (en) * 2016-05-12 2017-04-19 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Anticancer drug based on niclosamide
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
CA3052639A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CA3086185A1 (en) 2017-12-20 2019-06-27 Allergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for treatments of fibrosis associated disorders
FI3849614T3 (en) 2018-09-11 2024-02-08 Ambrx Inc Interleukin-2 polypeptide conjugates and their uses
JP2022512746A (en) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド Interleukin-10 polypeptide complex, its dimer, and their use
BR112021015832A2 (en) 2019-02-12 2022-01-18 Ambrx Inc Compositions containing antibody-tlr agonist conjugates, methods and uses thereof
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5066772A (en) * 1987-12-17 1991-11-19 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
CA2040141C (en) * 1990-04-13 2002-05-14 Minoru Yamada Biodegradable high-molecular polymers, production and use therof
FR2671562B1 (en) * 1991-01-16 1995-09-15 Oreal PROCESS FOR DIAGNOSING A CONDITION OF INFLAMMATION OR CELLULAR AGING OF KERATINOCYTES, AND NECESSARY FOR THE IMPLEMENTATION OF THIS PROCESS.
JP3011768B2 (en) * 1992-02-28 2000-02-21 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Photopolymerizable biodegradable hydrophilic gels as tissue contacting materials and controlled release carriers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
CA2118520C (en) * 1992-04-24 1999-08-10 Dirkjan Bakker Devices for preventing tissue adhesion
SG52402A1 (en) * 1992-12-22 1998-09-28 Univ Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
JPH09500132A (en) * 1993-07-12 1997-01-07 ヴァイラス リサーチ インスティチュート Hydrogel microencapsulated vaccine
BR9507313A (en) * 1994-04-08 1997-10-07 Atrix Lab Inc Liquid-release composition suitable for the formation of a controlled-release implant biodegradable microporous film dressing polymeric controlled-release implant precursor for implantation in an individual thermoplastic polymer organic solvent liquid pre-polymer composition controlled-release component active agent use of liquid release composition and processes to form an extended release microporous implant and to release an active agent in an individual
EP0717999A1 (en) * 1994-12-19 1996-06-26 The University Of Miami Drug delivery composition

Also Published As

Publication number Publication date
DK0830859T3 (en) 2004-04-05
EP1247522B1 (en) 2004-05-19
PT830859E (en) 2004-04-30
DE69729228D1 (en) 2004-06-24
CA2213368C (en) 2008-04-01
EP0830859A3 (en) 1998-07-22
DE69726672D1 (en) 2004-01-22
EP0830859A2 (en) 1998-03-25
ES2221916T3 (en) 2005-01-16
ES2212037T3 (en) 2004-07-16
DE69726672T2 (en) 2004-10-07
EP1247522A1 (en) 2002-10-09
DE69729228T2 (en) 2005-05-04
PT1247522E (en) 2004-10-29
EP0830859B1 (en) 2003-12-10
DK1247522T3 (en) 2004-09-27
WO1998006439A1 (en) 1998-02-19
US5980948A (en) 1999-11-09
ATE267006T1 (en) 2004-06-15
ATE255884T1 (en) 2003-12-15

Similar Documents

Publication Publication Date Title
CA2213368A1 (en) Polyetherester copolymers as drug delivery matrices
GR3021627T3 (en) Pharmaceutical formulations of osteogenic proteins
CA2355657A1 (en) Biodegradable ph/thermosensitive hydrogels for sustained delivery of biologically active agents
CA2304976A1 (en) Delivery of poly(ethylene glycol)-conjugated molecules from degradable hydrogels
CA2153584A1 (en) Cytokine restraining agents
AU1819499A (en) Positively-charged poly{alpha-(omega-aminoalkyl)glycolic acid} for the delivery of a bioactive agent via tissue and cellular uptake
WO1997014806A3 (en) Delivery of biologically active polypeptides
CA2329768A1 (en) Pharmaceutical composition comprising factor viii and neutral liposomes
EP1025840A3 (en) Oral drug compositions and methods
AU3822497A (en) Temperature sensitive gel for sustained delivery of protein drugs
AU9617698A (en) Polymeric systems for drug delivery and uses thereof
HUP0002381A3 (en) Apolipoprotein a-1 agonist peptide derivatives, complexes thereof and pharmaceutical compositions comprising their
CA2255691A1 (en) Cosmetic or pharmaceutical preparations with a reduced feeling of stickiness
MX9700851A (en) Adenovirus comprising a gene coding for glutathion peroxidase.
CA2325983A1 (en) Drug delivery of proteins from polymeric blends
HK1029928A1 (en) Pharmaceutical compositions of peptides having lowsolubility in physiological medium.
CA2273272A1 (en) Immediate release drug delivery forms
CA2185883A1 (en) The use of dimeticone as a transport and carrier system and/or drug delivery system
WO1998052590A3 (en) Improved delivery of disease modifiers
CA2205564A1 (en) Pharmaceutical compositions comprising nitric oxide-releasing biopolymers
ATE395101T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PROTEINS AND/OR POLYPEPTIDES AND COLLOID PARTICLES
HUP0000812A3 (en) Peptide fragments of myelin basic protein, their pharmaceutical compositions and their use in treating multiple sclerosis
MX9604539A (en) Modified amino acids for drug delivery.
AU9737198A (en) Pharmaceutical composition comprising 3,4-diarylchromans in low dose

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170818

MKLA Lapsed

Effective date: 20170818